The contrast-enhanced CT also improves lesion conspicuity over standard care of monophasic portovenous CT.
Dynamic contrast-enhanced CT increased the detection of colorectal liver metastasis, especially for lesions smaller than 15 mm, according to a study published in the European Journal of Radiology.
Researchers from Belgium performed a prospective study to evaluate a dynamic contrast-enhanced CT-protocol and compare this method with standard of care monophasic portovenous CT for detection of colorectal liver metastases.
Related article: Dynamic Contrast-Enhanced, Susceptibility Contrast MR Images Help Grade Gliomas
A total of 135 treatment-naïve patients participated in the study. All underwent dynamic contrast-enhanced CT, followed by routine monophasic portovenous CT of thorax-abdomen-pelvis. Forty-two of the patients presented with liver metastasis. The number and lesion conspicuity of detected liver metastasis on dynamic contrast-enhanced CT using perfusion maps was compared to monophasic CT.
The results showed that dynamic contrast-enhanced CT outperformed portovenous CT for detection as well as conspicuity of colorectal liver metastasis, at a relatively low dose increment.
The researchers concluded that using dynamic contrast-enhanced CT increased the detection of colorectal liver metastasis, especially for lesions smaller than 15 mm, when compared to monophasic portovenous CT. Dynamic contrast-enhanced CT also has the added advantage of improved lesion conspicuity, which can positively influence reader confidence and clinical workflow.
New Study Examines Agreement Between Radiologists and Referring Clinicians on Follow-Up Imaging
November 18th 2024Agreement on follow-up imaging was 41 percent more likely with recommendations by thoracic radiologists and 36 percent less likely on recommendations for follow-up nuclear imaging, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.